...
首页> 外文期刊>Journal of Clinical Microbiology >Improvements in detection of antibody to hepatitis B core antigen by treating specimens with reducing agent in an automated microparticle enzyme immunoassay.
【24h】

Improvements in detection of antibody to hepatitis B core antigen by treating specimens with reducing agent in an automated microparticle enzyme immunoassay.

机译:通过在自动化微粒酶免疫分析中用还原剂处理标本,改进了对乙型肝炎核心抗原的抗体检测。

获取原文
           

摘要

A fully automated microparticle enzyme immunoassay (EIA), IMx Core, was developed for the detection of antibody against hepatitis B core antigen (anti-HBc). IMx Core sensitivity was less than 0.5 Paul Ehrlich Institut units per ml and was greater than that of the commercial radioimmunoassay (RIA) or EIA, Corab and Corzyme, respectively. Specimens from blood donors and diagnostic and hospital patients, which included individuals with a variety of infectious and immune diseases, were tested in parallel by the IMx Core and EIA. Overall agreement of 99.1% (4,797 of 4,841) was obtained. Prevalence of anti-HBc tested by IMx Core ranged from 1.2% in volunteer blood donors to 9.1% in hospital laboratories. Discordant specimens reactive by IMx Core but negative by Corzyme or Corab resulted from the increased sensitivity of the IMx Core assay, since other hepatitis B markers were usually present. However, most discordant specimens were positive by the EIA or RIA but negative by IMx Core. No other hepatitis B markers could be detected in these discordants, and after addition of reducing agent, these specimens also became negative by EIA or RIA. In clinical trials, 30% (14 of 47) of volunteer blood donors and 8% (9 of 119) of hospital patients testing repeatedly reactive by the EIA had reduction-sensitive (unspecific) anti-HBc reactivity. The reducing agent, dithiothreitol, was added to each specimen automatically in the IMx assay to eliminate these unspecific reactions without significantly affecting anti-HBc reactivity resulting from hepatitis B virus infection as judged by the correlation with other hepatitis B markers.
机译:开发了一种全自动微粒酶免疫测定(IMA Core),用于检测针对乙型肝炎核心抗原的抗体(anti-HBc)。 IMx Core灵敏度低于每毫升0.5 Paul Ehrlich Institut单位,并且分别高于商业放射免疫分析(RIA)或EIA,Corab和Corzyme。 IMx Core和EIA并行测试了来自献血者,诊断和医院患者的样本,其中包括患有多种感染和免疫疾病的个体。总体同意率为99.1%(4,841,共4,797)。由IMx Core测试的抗HBc患病率从自愿献血者的1.2%到医院实验室的9.1%不等。 IMx Core具有反应性而Corzyme或Corab呈阴性,而IMx Core检测呈阴性,这是因为通常存在其他乙型肝炎标志物,从而导致不一致的标本发生反应。但是,大多数不一致的标本在EIA或RIA中为阳性,而在IMx Core中为阴性。在这些不和谐中无法检测到其他乙型肝炎标志物,并且在添加还原剂后,这些样品也被EIA或RIA变为阴性。在临床试验中,有30%(47名患者中的14名)的自愿献血者和8%(119名患者中的9名)的患者经EIA反复检测具有抗还原性(非特异性)抗HBc反应性。还原剂二硫苏糖醇在I​​Mx分析中自动添加到每个样本中,以消除这些非特异性反应,而不会显着影响由乙型肝炎病毒感染引起的抗HBc反应性,这是通过与其他乙型肝炎标志物的相关性判断的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号